|
Age (years)
|
47.8 ± 1.0
|
48.8 ± 2.0
|
0.651
|
|
Gender (male)
|
114 (55.1 %)
|
40 (52.6 %)
|
0.715
|
|
Race (not Caucasian)
|
24 (11.6 %)
|
9 (11.8 %)
|
0.954
|
|
Characteristics of interest
|
|
BMI (kg/m2)
|
30.9 ± 0.5
|
28.9 ± 0.1
|
0.025
|
|
Current smoker
|
78 (37.7 %)
|
14 (18.4 %)
|
0.002
|
|
Dyslipidemia
|
110 (53.1 %)
|
28 (36.8 %)
|
0.022
|
|
Systolic blood pressure
|
131 ± 1.3
|
123 ± 2.2
|
0.002
|
|
Fasting blood glucose (mg/dL)
|
94.7 ± 1.7
|
91.6 ± 1.4
|
0.184
|
|
HDL (mg/dL)
|
51.1 ± 1.0
|
55.9 ± 1.5
|
0.009
|
|
Hypertension
|
95 (45.9 %)
|
19 (25.0 %)
|
0.001
|
|
hsCRP
|
5.6 ± 0.7
|
3.3 ± 1.0
|
0.003
|
|
LDL (mg/dL)
|
121.2 ± 2.5
|
110.4 ± 3.9
|
0.027
|
|
Statin therapy
|
44 (21.3 %)
|
16 (21.1 %)
|
0.97
|
|
Total cholesterol (mg/dL)
|
197.4 ± 3.0
|
188.9 ± 4.7
|
0.128
|
|
Triglyceride (mg/dL)
|
125.9 ± 5.4
|
115.2 ± 11.3
|
0.392
|
|
Waist circumference (in)
|
40.2 ± 0.5
|
38.4 ± 0.6
|
0.028
|
|
Coronary artery calcium (CAC)
|
159 ± 32
|
130 ± 52
|
0.649
|
|
10 year Framingham risk score
|
5.8 ± 0.4
|
4.8 ± 0.8
|
0.235
|
|
Psoriasis specific
|
|
BSA
|
14.3 ± 1.3
|
N/A
|
ND
|
|
PASI
|
10 ± 0.7
|
N/A
|
ND
|
|
PGA
|
2.2 ± 0.1
|
N/A
|
ND
|
|
Psoriasis arthritis
|
51 (24.6 %)
|
N/A
|
ND
|
|
Psoriasis duration (years)
|
19.4 ± 1.0
|
N/A
|
ND
|
|
Psoriasis treatment(s)
|
|
Biologics
|
49 (23.7 %)
|
N/A
|
ND
|
|
Cyclosporine
|
5 (2.4 %)
|
N/A
|
ND
|
|
Methotrexate
|
13 (6.3 %)
|
N/A
|
ND
|
|
Narrow band UVB
|
13 (6.3 %)
|
N/A
|
ND
|
|
Oral retinoids
|
7 (3.4 %)
|
N/A
|
ND
|
|
Topicals
|
96 (46.4 %)
|
N/A
|
ND
|
